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Gottfried et al reported in this issue of Journal of Thoracic Oncology a randomizedstudy on a three-drug cisplatin-based combination chemotherapy (NIP) as induction
and adjuvant therapy for locally advanced non–small-cell lung cancer.1 The primary
objectives were to test the activity of three induction cycles of a new schedule of
intravenous vinorelbine in combination with ifosphamide and cisplatin (NIP) in stage III
A/B disease and to assess whether two additional cycles of therapy after surgery increased
survival compared with observation.
It is crucial to ask the right question in clinical trial design. The same first author
reported a phase II study on NIP as neoadjuvant therapy for local advanced disease in
1997.2 The response rate was 61%, and the median survival was 21.4 months. On the basis
of these results, the authors might have asked if NIP is better than other third-generation
based doublet/triplet as induction chemotherapy; or if NIP should be given as neoadjuvant
versus adjuvant therapy. Instead, the authors varied the schedule of NIP and found that the
neoadjuvant results of the current study were only similar and not superior to their
previous phase II study. They reported a response rate of 57.3% and a resection rate of
71% with this triplet. Compared with response rates of neoadjuvant third-generation
doublets ranging from 40 to 74% and resection rates ranging from 48 to 86%, NIP does
not appear to be superior to doublets.3 It was well intended to confirm the efficacy of NIP
as neoadjuvant therapy, but the study design has limited its value.
The second key question they attempted to address is whether an addition of two
cycles of adjuvant chemotherapy would improve survival of patients who had completed
induction chemotherapy followed by surgical resection for locally advanced disease. This
is an important question that should be addressed by an adequately powered study. We
find the assumptions leading to a sample size of 124 randomized patients to be unrealistic.
The 2-year survival rate of patients who had completed neoadjuvant chemotherapy
followed by surgery should be higher than 25%. The median survival of their own phase
II study2 was 21.4 months, meaning that 50% of the study population was alive at this
time. It would be unlikely that the remaining 25% of subjects died within 2.6 months. The
projected improvement of the 2-year survival rate to 45% (a relative increase of 80%, and
a corresponding hazard ratio of approximately 0.60) by adding two cycles of postoperative
chemotherapy was also optimistic. None of the reported adjuvant studies has demonstrated
such a large benefit.4–6 An low survival estimate and an unrealistic estimate of improve-
ment lead to the decision for a smaller sample size (by a factor of at least 4) that in turn
ended up with an underpowered study for realistic but still important differences.
It is difficult if not impossible to address both neoadjuvant and adjuvant questions
in a single study.1 “Secondary randomization” that depended on the treatment outcome of
the neoadjuvant therapy and surgery complicates proper estimation of sample size at
primary enrollment. Only 107 out of 156 enrolled patients were eligible for surgery and
79 had complete resection. This is quite different from their original plan of enrolling 150
patients and randomizing 124 patients postoperatively. Resectability depended on subjec-
tive evaluation by surgeons and oncologists, which could be highly variable from center
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to center and country to country. This study involved 14
centers from 8 countries. The smaller than expected number
of randomized patients has precluded them from making a
conclusion on the role of NIP as adjuvant therapy.
Clinical trials are very expensive ventures. The cost of
pharmaceutical research and development has been skyrock-
eting in the past 10 years. The average cost per patient in a
United State-based clinical trial ranges from USD $5404 to
$7635.7 This cost will eventually be funneled to patients and
population at large. A futile clinical trial adds to the cost but
offers little new information in return. Investigators have the
responsibility to assure a top quality design before engaging
in a study. Pharmaceutical companies are the major or even
sole sponsors of many clinical trials and not infrequently
commercialization becomes intrinsic to study design. Inves-
tigators must keep the balance between the scientific merit
and commercial value of the clinical trial. This is the only
way to assure return of high quality knowledge and informa-
tion from the invested time, money, and patient resources.
Investigators are gate keepers. Before engaging in a
clinical trial, we must assure the feasibility and integrity of
the clinical trial by addressing a key question with a sound
hypothesis and realistic accrual plan.
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